Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 74,900 shares, a decrease of 92.5% from the January 31st total of 993,200 shares. Based on an average daily volume of 397,700 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.7% of the shares of the stock are short sold.

Aptose Biosciences Trading Down 1.8 %

Shares of Aptose Biosciences stock opened at $3.19 on Friday. Aptose Biosciences has a 52 week low of $3.05 and a 52 week high of $57.00. The stock has a market cap of $6.83 million, a PE ratio of -1.07 and a beta of 0.88. The company’s 50-day moving average price is $5.92 and its two-hundred day moving average price is $8.83.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com initiated coverage on Aptose Biosciences in a report on Tuesday. They set a “hold” rating on the stock.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.